Insuficiencia autónoma pura

1. Bradbury S, Eggleston C. Postural hypotension: a report of three cases. Am Heart J. 1925;1(1):73-86.

2. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy: the Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Neurology. 1996; 46(5):1470.

3. Kaufmann H, Norcliffe-Kaufmann L, Palma JA, et al. Natural history of pure autonomic failure: a United States prospective cohort. Ann Neurol. 2017;81(2):287-297.

4. Singer W, Berini SE, Sandroni P, et al. Pure autonomic failure: predictors of conversion to clinical CNS involvement. Neurology. 2017; 88 (12):1129-1136.

5. Polinsky RJ, Kopin IJ, Ebert MH, Weise V. Pharmacologic distinction of different orthostatic hypotension syndromes. Neurology. 1981;31(1):1-7.

6. Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension: a clinical-pathologic study. Arch Neurol. 1960;2:511-527.

7. Graham JG, Oppenheimer DR. Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy. J Neurol Neurosurg Psychiatry. 1969; 32(1):28-34.

8. Gilman S, Low PA, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. J Auton Nerv Syst. 1998; 74(2-3):189-192.

9. Bannister R, Ardill L, Fentem P. Defective autonomic control of blood vessels in idiopathic orthostatic hypotension. Brain. 1967; 90(4):725-746.

10. Thomas JE, Schirger A. Neurologic manifestations in idiopathic orthostatic hypotension. Arch Neurol. 1963;8:204-208.

11. Peelaerts W, Bousset L, Van der Perren A, et al. a-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature. 2015;522(7556):340-344.

12. Coon EA, Low PA. Pure autonomic failure without alphasynuclein pathology: an evolving understanding of a heterogeneous disease. Clin Auton Res. 2017; 27(2):67-68.

13. Dickson DW, Liu W, Hardy J, et al. Widespread alterations of alpha-synuclein in multiple system atrophy. Am J Pathol. 1999; 155(4):1241-1251.

14. Prusiner SB, Woerman AL, Mordes DA, et al. Evidence for asynuclein prions causing multiple system atrophy in humans with parkinsonism. Proc Natl Acad Sci U S A. 2015; 112(38): E5308-E5317.

15. Hague K, Lento P, Morgello S, Caro S, Kaufmann H. The distribution of Lewy bodies in pure autonomic failure: autopsy findings and review of the literature. Acta Neuropathol. 1997; 94(2): 192-196.

16. Arai K, Kato N, Kashiwado K, Hattori T. Pure autonomic failure in association with human alpha-synucleinopathy. Neurosci Lett. 2000;296(2-3):171-173.

17. Kontos HA, Richardson DW, Norvell JE. Norepinephrine depletion in idiopathic orthostatic hypotension. Ann Intern Med. 1975;82(3):336-341.

18. Bannister R, Crowe R, Eames R, Burnstock G. Adrenergic innervation in autonomic failure. Neurology. 1981; 31(12): 1501-1506.

19. Roessmann U, Van den Noort S, McFarland DE. Idiopathic orthostatic hypotension. Arch Neurol. 1971;24(6):503-510.

20. van Ingelghem E, van Zandijcke M, Lammens M. Pure autonomic failure: a new case with clinical, biochemical, and necropsy data. J Neurol Neurosurg Psychiatry. 1994; 57(6):745-747.

21. Kaufmann HC, Benarroch EE. Degenerative autonomic disorders (autonomic synucleinopathies). In: Low PA, Benarroch EE, eds. Clinical Autonomic Disorders. 3rd ed. Baltimore, MA: Lippincott Williams & Wilkins; 2008:287-306.

22. Shishido T, Ikemura M, Obi T, et al. a-Synuclein accumulation in skin nerve fibers revealed by skin biopsy in pure autonomic failure. Neurology. 2010;74(7):608-610.

23. Donadio V, Incensi A, Piccinini C, et al. Skin nerve misfolded asynuclein in pure autonomic failure and Parkinson disease. Ann Neurol. 2016;79(2):306-316.

24. Donadio V, Cortelli P, Elam M, et al. Autonomic innervation in multiple system atrophy and pure autonomic failure. J Neurol Neurosurg Psychiatry. 2010; 81(12):1327-1335.

25. Lee JM, Derkinderen P, Kordower JH, et al. The search for a peripheral biopsy indicator of a-synuclein pathology for Parkinson disease. J Neuropathol Exp Neurol. 2017; 76(1):2-15.

26. Isonaka R, Holmes C, Cook GA, Sullivan P, Sharabi Y, Goldstein DS. Pure autonomic failure without synucleinopathy. Clin Auton Res. 2017;27(2):97-101.

27. Goldstein DS, Eisenhofer G, Kopin IJ. Sources and significance of plasma levels of catechols and their metabolites in humans. J Pharmacol Exp Ther. 2003;305(3):800-811.

28. Goldstein DS, Holmes C, Imrich R. Clinical laboratory evaluation of autoimmune autonomic ganglionopathy: preliminary observations. Auton Neurosci. 2009; 146(1-2):18-21.

29. Yamamoto T, Polinsky RJ, Goldstein DS, Baucom CE, Kopin IJ. Plasma sulfoconjugated dopamine levels are normal in patients with autonomic failure. J Lab Clin Med. 1996; 128(5):488-491.

30. Goldstein DS, Holmes C, Sharabi Y. Cerebrospinal fluid biomarkers of central catecholamine deficiency in Parkinson’s disease and other synucleinopathies. Brain. 2012; 135(pt 6): 1900-1913.

31. Biaggioni I, Onrot J, Stewart CK, Robertson D. The potent pressor effect of phenylpropanolamine in patients with autonomic impairment. JAMA. 1987; 258(2):236-239.

32. Freeman R. Pure autonomic failure. In: Robertson D, Biaggiona I, eds. Disorders of the Autonomic Nervous System. Luxembourg: Harwood Academic Publishers; 1995:83-105.

33. Robertson D, Hollister AS, Carey EL, Tung CS, Goldberg MR, Robertson RM. Increased vascular beta2-adrenoceptor responsiveness in autonomic dysfunction. J Am Coll Cardiol. 1984; 3(3): 850-856.

34. Gupta D, Nair MD. Neurogenic orthostatic hypotension: chasing “the fall”. Postgrad Med J. 2008; 84(987):6-14.

35. Mathias CJ. Autonomic nervous system: clinical testing. In: Squire LR, ed. Encyclopedia of Neuroscience. Cambridge, MA: Academic Press; 2009:911-928.

36. Kaufmann H, Oribe E, Miller M, Knott P, Wiltshire-Clement M, Yahr MD. Hypotension-induced vasopressin release distinguishes between pure autonomic failure and multiple system atrophy with autonomic failure. Neurology. 1992; 42(3, pt 1): 590-593.

37. Goldstein DS, Holmes C, Cannon RO III, Eisenhofer G, Kopin IJ. Sympathetic cardioneuropathy in dysautonomias. N Engl J Med. 1997; 336(10):696-702.

38. Goldstein DS, Holmes CS, Dendi R, Bruce SR, Li ST. Orthostatic hypotension from sympathetic denervation in Parkinson’s disease. Neurology. 2002; 58(8):1247-1255.

39. Goldstein DS, Sewell L. Olfactory dysfunction in pure autonomic failure: implications for the pathogenesis of Lewy body diseases. Parkinsonism Relat Disord. 2009; 15(7):516-520.

40. Tipre DN, Goldstein DS. Cardiac and extracardiac sympathetic denervation in Parkinson’s disease with orthostatic hypotension and in pure autonomic failure. J Nucl Med. 2005; 46(11):1775-1781.

41. Goldstein DS. Sympathetic neuroimaging. Handb Clin Neurol. 2013; 117:365-370.

42. Braune S. The role of cardiac metaiodobenzylguanidine uptake in the differential diagnosis of parkinsonian syndromes. Clin Auton Res. 2001; 11(6):351-355.

43. Sawada H, Oeda T, Yamamoto K, et al. Diagnostic accuracy of cardiac metaiodobenzylguanidine scintigraphy in Parkinson disease. Eur J Neurol. 2009; 16(2):174-182.